Axsome CFO’s $3.50 Buy & $187.92 Sell Signals Strong Insider Confidence on 21% Rally
Axsome CFO’s 12,000‑share buy‑sell cycle shows confident insider bets on the drug pipeline, with strategic 10(b)(5)(1) trades that signal long‑term optimism and clear liquidity management.
3 minutes to read